We are thrilled to share the news from our friends at ForeBatten that the FDA have provided IND clearance for the clinical investigation for Zebronkysen (FBF-001) under the N-of-1 guidance for individualized Antisense Oligonucleotide (ASO) drug products. Two patients with the unique CLN3 c.569dupG mutation began treatment in June, 2024.
To read more about this significant milestone, see below.
To find out more about ASOs, check out this 2-minute clip from Harvard Medical School: https://youtu.be/p8KFtND911A?si=nqc__P2TcwPxCrtR
